• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    10 Health Care Stocks With Whale Alerts In Today's Session

    6/11/24 1:35:23 PM ET
    $ABBV
    $AVTR
    $FULC
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $ABBV alert in real time by email

    This whale alert can help traders discover the next big trading opportunities.

    Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

    Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels.

    Below are some instances of options activity happening in the Health Care sector:

    Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume
    FULC PUT TRADE BULLISH 06/21/24 $7.00 $141.2K 50 1.4K
    GTHX PUT SWEEP BEARISH 07/19/24 $1.50 $39.7K 727 451
    UTHR CALL TRADE BEARISH 11/15/24 $320.00 $25.2K 6 299
    LLY PUT TRADE BEARISH 03/21/25 $650.00 $483.0K 115 279
    IBRX CALL TRADE BEARISH 01/17/25 $5.50 $43.2K 1.5K 236
    MDGL CALL SWEEP BULLISH 10/18/24 $410.00 $41.0K 6 201
    MCK CALL TRADE BULLISH 11/15/24 $600.00 $43.1K 36 13
    ISRG CALL SWEEP BULLISH 06/20/25 $540.00 $25.3K 36 7
    ABBV PUT SWEEP BEARISH 09/20/24 $165.00 $26.7K 2.8K 6
    AVTR PUT SWEEP BEARISH 06/21/24 $23.00 $171.9K 19.5K 3

    Explanation

    These itemized elaborations have been created using the accompanying table.

    • For FULC (NASDAQ:FULC), we notice a put option trade that happens to be bullish, expiring in 10 day(s) on June 21, 2024. This event was a transfer of 3532 contract(s) at a $7.00 strike. The total cost received by the writing party (or parties) was $141.2K, with a price of $40.0 per contract. There were 50 open contracts at this strike prior to today, and today 1470 contract(s) were bought and sold.

    • Regarding GTHX (NASDAQ:GTHX), we observe a put option sweep with bearish sentiment. It expires in 38 day(s) on July 19, 2024. Parties traded 722 contract(s) at a $1.50 strike. This particular put needed to be split into 27 different trades to become filled. The total cost received by the writing party (or parties) was $39.7K, with a price of $55.0 per contract. There were 727 open contracts at this strike prior to today, and today 451 contract(s) were bought and sold.

    • For UTHR (NASDAQ:UTHR), we notice a call option trade that happens to be bearish, expiring in 157 day(s) on November 15, 2024. This event was a transfer of 26 contract(s) at a $320.00 strike. The total cost received by the writing party (or parties) was $25.2K, with a price of $970.0 per contract. There were 6 open contracts at this strike prior to today, and today 299 contract(s) were bought and sold.

    • For LLY (NYSE:LLY), we notice a put option trade that happens to be bearish, expiring in 283 day(s) on March 21, 2025. This event was a transfer of 322 contract(s) at a $650.00 strike. The total cost received by the writing party (or parties) was $483.0K, with a price of $1500.0 per contract. There were 115 open contracts at this strike prior to today, and today 279 contract(s) were bought and sold.

    • For IBRX (NASDAQ:IBRX), we notice a call option trade that happens to be bearish, expiring in 220 day(s) on January 17, 2025. This event was a transfer of 225 contract(s) at a $5.50 strike. The total cost received by the writing party (or parties) was $43.2K, with a price of $192.0 per contract. There were 1577 open contracts at this strike prior to today, and today 236 contract(s) were bought and sold.

    • For MDGL (NASDAQ:MDGL), we notice a call option sweep that happens to be bullish, expiring in 129 day(s) on October 18, 2024. This event was a transfer of 50 contract(s) at a $410.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $41.0K, with a price of $820.0 per contract. There were 6 open contracts at this strike prior to today, and today 201 contract(s) were bought and sold.

    • For MCK (NYSE:MCK), we notice a call option trade that happens to be bullish, expiring in 157 day(s) on November 15, 2024. This event was a transfer of 13 contract(s) at a $600.00 strike. The total cost received by the writing party (or parties) was $43.1K, with a price of $3320.0 per contract. There were 36 open contracts at this strike prior to today, and today 13 contract(s) were bought and sold.

    • Regarding ISRG (NASDAQ:ISRG), we observe a call option sweep with bullish sentiment. It expires in 374 day(s) on June 20, 2025. Parties traded 14 contract(s) at a $540.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $25.3K, with a price of $1810.0 per contract. There were 36 open contracts at this strike prior to today, and today 7 contract(s) were bought and sold.

    • For ABBV (NYSE:ABBV), we notice a put option sweep that happens to be bearish, expiring in 101 day(s) on September 20, 2024. This event was a transfer of 50 contract(s) at a $165.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $26.7K, with a price of $535.0 per contract. There were 2815 open contracts at this strike prior to today, and today 6 contract(s) were bought and sold.

    • For AVTR (NYSE:AVTR), we notice a put option sweep that happens to be bearish, expiring in 10 day(s) on June 21, 2024. This event was a transfer of 5000 contract(s) at a $23.00 strike. This particular put needed to be split into 33 different trades to become filled. The total cost received by the writing party (or parties) was $171.9K, with a price of $35.0 per contract. There were 19536 open contracts at this strike prior to today, and today 3 contract(s) were bought and sold.

    Options Alert Terminology
    - Call Contracts: The right to buy shares as indicated in the contract.
    - Put Contracts: The right to sell shares as indicated in the contract.
    - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it.
    - Premium/Option Price: The price of the contract.

    For more information, visit our Guide to Understanding Options Alerts or read more news on unusual options activity.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABBV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABBV
    $AVTR
    $FULC
    $GTHX

    CompanyDatePrice TargetRatingAnalyst
    Eli Lilly and Company
    $LLY
    3/17/2026$850.00Hold → Reduce
    HSBC Securities
    ImmunityBio Inc.
    $IBRX
    3/12/2026$13.00Buy
    BTIG Research
    Intuitive Surgical Inc.
    $ISRG
    3/11/2026$590.00Neutral → Buy
    Citigroup
    Avantor Inc.
    $AVTR
    3/6/2026$8.50Equal Weight → Underweight
    Barclays
    Eli Lilly and Company
    $LLY
    2/25/2026$1250.00Outperform
    RBC Capital Mkts
    AbbVie Inc.
    $ABBV
    2/25/2026$260.00Outperform
    RBC Capital Mkts
    Eli Lilly and Company
    $LLY
    2/20/2026$1350.00Overweight
    Barclays
    AbbVie Inc.
    $ABBV
    2/20/2026$275.00Overweight
    Barclays
    More analyst ratings

    $ABBV
    $AVTR
    $FULC
    $GTHX
    SEC Filings

    View All

    SEC Form DEFA14A filed by Intuitive Surgical Inc.

    DEFA14A - INTUITIVE SURGICAL INC (0001035267) (Filer)

    3/13/26 5:22:51 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    SEC Form DEF 14A filed by Intuitive Surgical Inc.

    DEF 14A - INTUITIVE SURGICAL INC (0001035267) (Filer)

    3/13/26 5:16:52 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    United Therapeutics Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - UNITED THERAPEUTICS Corp (0001082554) (Filer)

    3/9/26 5:18:10 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AVTR
    $FULC
    $GTHX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Eli Lilly downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded Eli Lilly from Hold to Reduce and set a new price target of $850.00

    3/17/26 7:55:56 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research resumed coverage on ImmunityBio with a new price target

    BTIG Research resumed coverage of ImmunityBio with a rating of Buy and set a new price target of $13.00

    3/12/26 8:52:16 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Intuitive Surgical upgraded by Citigroup with a new price target

    Citigroup upgraded Intuitive Surgical from Neutral to Buy and set a new price target of $590.00

    3/11/26 8:28:54 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    $ABBV
    $AVTR
    $FULC
    $GTHX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    10/18/24 4:38:13 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form

    10/17/24 1:29:31 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SKYRIZI issued to ABBVIE INC

    Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-7) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/18/2024. Application Category: BLA, Application Number: 761262, Application Classification:

    6/21/24 4:38:17 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AVTR
    $FULC
    $GTHX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lucier Gregory T bought $458,000 worth of shares (50,000 units at $9.16) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    2/23/26 8:53:53 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Summe Gregory L bought $940,000 worth of shares (100,000 units at $9.40) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    2/12/26 5:24:47 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Mehra Sanjeev K was granted 8,106 shares and bought $3,881,500 worth of shares (350,000 units at $11.09) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    12/9/25 5:11:24 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ABBV
    $AVTR
    $FULC
    $GTHX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Rothblatt Martine A

    4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

    3/18/26 4:33:50 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairperson & CEO Rothblatt Martine A sold $5,072,019 worth of shares (9,500 units at $533.90) and exercised 9,500 shares at a strike of $146.03 (SEC Form 4)

    4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

    3/17/26 5:11:15 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT AND COO Benkowitz Michael covered exercise/tax liability with 14,706 shares and converted options into 33,382 shares (SEC Form 4)

    4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

    3/17/26 5:10:36 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AVTR
    $FULC
    $GTHX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease

    Recommendation is based on peer-reviewed clinical data supporting long-term effectiveness and safety durability in patients with papillary-only disease treated with ANKTIVA plus BCG1. ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today announced that the National Comprehensive Cancer Network (NCCN®) has updated its 2026 NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer to include ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary-only disease. This update expands previous NCCN clinical guideline r

    3/17/26 7:30:00 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis

    In the Phase 3 ADorable-1 study, 63% of patients achieved meaningful skin improvement (EASI-75) and 44% achieved clear or almost clear skin (IGA 0,1) at Week 16In key secondary endpoints, 39% of patients achieved a high bar of near-complete skin clearance (EASI-90) and 35% achieved significant itch relief (Pruritus NRS ≥4-point improvement)The safety and tolerability profile of EBGLYSS was consistent with adult and adolescent studies, with no injection site pain reportedINDIANAPOLIS, March 16, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced positive, topline results from the Phase 3 ADorable-1 trial evaluating the safety and efficacy of EBGLYSS (lebrikizumab-lbkz) in pe

    3/16/26 6:45:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

    New York, NY, March 13, 2026 (GLOBE NEWSWIRE) -- New York Plastic Surgical Group (NYPS Group) and Deep Blue Med Spa (DBMS) are proud to announce that they have once again been recognized by Allergan Aesthetics as the #1 provider in New York State, marking the second consecutive year earning this distinction. In addition, the practices have been ranked Top 50 in the nation for 2026, placing them among an elite group of aesthetic providers across the United States. This recognition reflects NYPS Group and Deep Blue Med Spa's continued leadership in aesthetic medicine and their longstanding commitment to delivering advanced, evidence-based treatments performed by highly trained medical profe

    3/13/26 9:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AVTR
    $FULC
    $GTHX
    Leadership Updates

    Live Leadership Updates

    View All

    McKesson Announces Planned CFO Transition

    Britt Vitalone announces retirement, Kenny Cheung named as successor McKesson Corporation (NYSE:MCK) today announced Britt Vitalone, Executive Vice President and Chief Financial Officer (CFO), has elected to retire after a successful and distinguished 20-year career with the company, including more than eight years as CFO. Looking ahead, Kenny Cheung will join McKesson as Executive Vice President and CFO, effective May 29, 2026. "Britt is an exceptional partner and leader. He has been instrumental in advancing the company's financial performance, engaging with shareholders, and instilling a culture of financial discipline," said Brian Tyler, Chief Executive Officer, McKesson Corporation

    3/5/26 8:10:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH

    SUZHOU, China and MÖLNDAL, Sweden, Feb. 11, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today announced that they have entered into an exclusive worldwide licensing agreement with Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) ("Madrigal") for six pre-clinical small interfering RNA (siRNA) programs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The collaboration will utilize Ribo's validated liver targeting siRNA GalSTARTM platform to develop novel treatm

    2/11/26 6:25:00 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AVTR
    $FULC
    $GTHX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Madrigal Pharmaceuticals Inc.

    SC 13G/A - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

    11/14/24 5:18:50 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Fulcrum Therapeutics Inc.

    SC 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)

    11/14/24 4:25:46 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    11/14/24 1:28:33 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ABBV
    $AVTR
    $FULC
    $GTHX
    Financials

    Live finance-specific insights

    View All

    McKesson Corporation Announces Fourth Quarter Fiscal 2026 Earnings Release Date and Participation in Upcoming Conferences

    McKesson Corporation (NYSE:MCK) will release its fourth quarter fiscal 2026 financial results after market close on Thursday, May 7, 2026. Chief Executive Officer Brian Tyler and Chief Financial Officer Britt Vitalone will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. Mr. Vitalone will be participating in Leerink Partners Global Healthcare Conference and Barclays Global Healthcare Conference on Wednesday, March 11, 2026. Mr. Vitalone will also participate in the BofA Securities 2026 Healthcare Conference in May 2026. McKesson Corporation has reaffirmed fiscal 2026 full year outlook as previously issued on Febru

    3/6/26 8:00:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026

    ImmunityBio, Inc. ((IBRX), today announced that it will host a live conference call at 1:30 p.m. Pacific Time on Tuesday, March 3, 2026, to provide a business update, including progress across the company's clinical trial pipeline, and to review financial results for the year ended December 31, 2025. Conference Call Details The conference call will begin at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on Tuesday, March 3, 2026. Interested parties may access the conference call through our Investor Relations website, ir.immunitybio.com, under Company — Events & Presentations. Alternatively, individuals can access the call by dialing 1-844-539-3703 or 1-412-652-1273 (internationally).

    2/27/26 7:30:00 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    United Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results

    United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2025. Full year 2025 revenues rose to a record $3.18 billion, reflecting 11% growth over 2024. "As we close out another remarkable year with record total revenue for the fourth year in a row, I extend my thanks to our Unitherians whose unwavering commitment to innovation and excellence fuels our mission," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "Looking ahead, our ADVANCE OUTCOMES and TETON-1 clinical programs are on the cusp of unveiling pivotal data that could unlock signific

    2/25/26 6:30:00 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care